1

An Issue of Argue with “Macromolecular Bioscience” (mabi.201600354) - [EMID:ede5826a460a4a62] Dr. David Huesmann, Editor Macromolecular Bioscience Email: macromol@wiley-vch.de Phone: +49 6201-606-581 http://mbs-journal.de/ ========================= Editorial Office, Macromolecular Journals Wiley-VCH Verlag GmbH & Co. KGaA Boschstrasse 12, 69469 Weinheim, Germany Email: macromol@wiley-vch.de Phone: +49 6201-606-581 Fax: +49 6201-606-510 Homepages & Full Text: http://www.macros.wiley-vch.de Best of Macromolecular Journals: http://best-of-macros.de (Free Access!) ---------- ***** Wiley-VCH Verlag GmbH & Co. KGaA – A company of John Wiley & Sons, Inc. - Location of the Company: Weinheim - Trade Register: Mannheim, HRB 432833. Chairman of the Supervisory Board: Mark Allin. General Partner: John Wiley & Sons GmbH, Location: Weinheim – Trade Register Mannheim, HRB 432296 – Managing Directors: Sabine Steinbach, Philip Carpenter ***** Dear Editor, Kindly be a little bit explicit for the due diligence process : Are you saying that : Advanced Glycation End Products have nothing in common with the Macromolecular Bioscience ? We are looking forward to hearing from you again.

2

Thank you. Cordially, Dr. Mark A. Babizhayev -------------------------------------------- On Fri, 8/19/16, MACRO <macromol@wiley-vch.de> wrote: Subject: AW: Your submission to Macromolecular Bioscience (mabi.201600354) - [EMID:ede5826a460a4a62] To: "Innovative Vision Products, Inc. Mark A. Babizhayev" <markbabizhayev2005@yahoo.com> Date: Friday, August 19, 2016, 1:33 PM Dear Dr. Babizhayev, your article falls outside of the scope of Macromolecular Bioscience and will therefore not be considered further. With kind regards, David Huesmann ========================= Editorial Office, Macromolecular Journals Wiley-VCH Verlag GmbH & Co. KGaA Boschstrasse 12, 69469 Weinheim, Germany Email: macromol@wiley-vch.de Phone: +49 6201-606-581 Fax: +49 6201-606-510 Homepages & Full Text: http://www.macros.wiley-vch.de Best of Macromolecular Journals: http://best-of-macros.de (Free Access!) ---------- MCP Special Issue "Young Talents in Polymer Science, Parts 1 & 2" guest-edited by Laura Hartmann, Bin Liu, Bradley D. Olsen http://doi.wiley.com/10.1002/macp.v217.2

3

http://doi.wiley.com/10.1002/macp.v217.3 MRC Special Issue "Advanced Functional Polymers Addressing the Needs of Modern Medicine" guest-edited by Andreas Lendlein and Abhay Pandit http://doi.wiley.com/10.1002/marc.v36.21 MRE Special Issue "Product Design of Hybrids" guest-edited by María Paulis, José M. Asua http://doi.wiley.com/10.1002/mren.v10.1 ---------- Bringing you tomorrow's materials science: http://MaterialsViews.com and http://MaterialsViewsChina.com ---------- ________________________________________ Von: Innovative Vision Products, Inc. Mark A. Babizhayev <markbabizhayev2005@yahoo.com> Gesendet: Donnerstag, 18. August 2016 14:59 An: Mark Babizhayev; MACRO Betreff: Your submission to Macromolecular Bioscience (mabi.201600354) - [EMID:ede5826a460a4a62] Dear Editor , Dear Dr. David Huesmann, Thank you for the provided comments which we feel to perceive as the very formal declaration. Recently, the certain appeals have been made to the President of the USA, Japanese Prime Minister Abe, HM British Queen Elizabeth II about the Genealogical studies inherent to Dr. Mark Babizhayev and the Members of his Family . The inheritance has been unequivocally proved with the number of

4

relevant modern and classical approaches. Dr. Mark Babizhayev is the Senior Great Grandson of Wallis Simpson (Bessie Wallis Warfield-Spencer-Simpson) USA wife of Edward VIII & King of UK Edward VIII “David” (Edward Albert Christian George Andrew Patrick David) Prince of Wales UK, Duke & Duchess of Windsor . In other words, Dr. Mark Babizhayev has an "Unofficial Status of a King of UK" and is the Major relative of the British Royal Family. Here are below the Illustration Photos : The Upper Image :

The Image of the King George V. George V (George Frederick Ernest Albert; 3 June 1865 – 20 January 1936) was King of the United Kingdom and the British Dominions, and Emperor of India, from 6 May 1910 until his death in 1936.

He was the second son of Albert Edward, Prince of Wales (later King Edward VII), and the grandson of the reigning British monarch, Queen Victoria.

5

The Lower Image:

Dr. Mark Babizhayev in Monte Carlo (An Individual placed in the centre of the Image), Principauté De Monaco

6

*** The Next pair of the Guiding Photos : The Upper Image: Dr. Mark A. Babizhayev in Germany (Bonn) The Lower image

Edward VII (Albert Edward; 9 November 1841 – 6 May 1910) was King of the United Kingdom and the British Dominions and Emperor of India from 22 January 1901 until his death in 1910.

The eldest son of Queen Victoria and Prince Albert of Saxe-Coburg and Gotha, Edward was related to royalty throughout Europe. Before his accession to the throne, he served as heir apparent and held the title of Prince of Wales for longer than any of his predecessors.

7

8

Here are below the third pair of the Illustration Photos : The Upper image

Edward VII (Albert Edward; 9 November 1841 – 6 May 1910) was King of the United Kingdom and the British Dominions and Emperor of India from 22 January 1901 until his death in 1910.

The eldest son of Queen Victoria and Prince Albert of Saxe-Coburg and Gotha, Edward was related to royalty throughout Europe. Before his accession to the throne, he served as heir apparent and held the title of Prince of Wales for longer than any of his predecessors.

9

Dr. Mark Babizhayev in the State of Philadlephia, The United States of America

10

The phenotypic resemblance of Dr. Mark Babizhayev to the main Kings of the UK is obvious for Everybody… The detailed data are described shortly on The Twitter : Albert II Grimaldi@markinmonaco . https://twitter.com/markinmonaco/with_replies We invite you to publish our work in your scientific vehicle/Journal as it is, in view of the above Official assumption, regardless the Subjective opinions of your Staff/yours provided below. Please, make the following note upon the Publication of the Materials making the asterisk symbol and disclosure following the title of the Article : Dr. Mark Babizhayev is the Senior Great Grandson of Wallis Simpson (Bessie Wallis Warfield-Spencer-Simpson) USA wife of Edward VIII & King of UK Edward VIII “David” (Edward Albert Christian George Andrew Patrick David) Prince of Wales UK, Duke & Duchess of Windsor . In other words, Dr. Mark Babizhayev has an "Unofficial Status of a King of UK" and is the Major relative of the British Royal Family. If we would not hear the positive answer from your Staff at soonest, being appropriate, we will raise the Public Discussion against your Journal through the Washington Post and other important International platforms through Twitter, accordingly. Please, review the Twitter account of our Group : https://twitter.com/markinmonaco/with_replies Note, that the materials of the submission have been patented by the Author according to the PCT system. After we manage to start and act against your Staff in the mentioned above way, if you fail to comply with our Requirements of publication,

11

we predict that your Journal would be most probably removed from the Public Domain based on the importance of the considered issues. You will not gain from your rejection, neither you will be able to save space in your Journal dedicated to another (more "preferable") submissions. We are very interested to hear your next comments. Thank you. Cordially, Dr. Mark Babizhayev -------------------------------------------- On Thu, 8/18/16, Macromolecular Bioscience <em@editorialmanager.com> wrote: Subject: Your submission to Macromolecular Bioscience (mabi.201600354) - [EMID:ede5826a460a4a62] To: "Mark Babizhayev" <markbabizhayev2005@yahoo.com> Date: Thursday, August 18, 2016, 4:17 PM Dear Dr. Babizhayev, Thank you for submitting your manuscript "Advanced Glycation End Products : Regulation, Function and Role in Health and Disease. Free Radical Generation by Early Glycation Products as a Mechanism for Long-Term Complications of Diabetes Mellitus" (mabi.201600354) to Macromolecular Bioscience. Unfortunately, we are not able to consider it further for publication. As we receive many more manuscripts than we can possibly publish, or even send out for review, we are forced to adopt a stringent selection process. We therefore can only select those manuscripts we believe will interest the broadest possible section of our readership and represent a significant breakthrough of general interest.

12

We therefore did not want to delay this decision and wish you success in submission of the manuscript to another journal. Thank you for considering Macromolecular Bioscience. Yours sincerely, David Huesmann ----- Dr. David Huesmann, Editor Macromolecular Bioscience Email: macromol@wiley-vch.de Phone: +49 6201-606-581 http://mbs-journal.de/ ***** Have you seen our new interdisciplinary premium open access journal Advanced Science? For more information or to submit now go to www.advancedscience.com ***** Wiley-VCH Verlag GmbH & Co. KGaA – A company of John Wiley & Sons, Inc. - Location of the Company: Weinheim - Trade Register: Mannheim, HRB 432833. Chairman of the Supervisory Board: Mark Allin. General Partner: John Wiley & Sons GmbH, Location: Weinheim – Trade Register Mannheim, HRB 432296 – Managing Directors: Sabine Steinbach, Philip Carpenter ***** ***** ***

13

Declaration on Patenting, Originality and Linguistics Dear Editors , Dear Sir/Madam , Please, consider below our Declaration of Interest/Explanation : The main concern of the originality raised during the application and uses CrossCheck powered by iThenticate software is the subject of plagiarism. This programme is dedicated to reveal the subjects of plagiarism in the submitted manuscripts. The application of iThenticate programme to the current case is prohibited as there is no traces of plagiarism in the contents of this article supported by the filed and issued Patents according to the PCT International system cited below. See below the more detailed description of the case. The Journal employs a plagiarism detection system. By submitting the manuscript to the Journal one accepts that the submitted manuscript may be screened for plagiarism. However, kindly note that this subject of originality is not sufficient and is not legally applicable to the current submitted article and to this considered case. The reason of this is as follows : The clue moment of the raised dispute with your Journal is the point about plagiarism. If it is officially clear that there are NO traces of plagiarism in the submitted article that is supported by the presented and clearly cited in the scope of the Manuscript PCT patent applications which privilege the priority of the Authors in this field and the absence of the prior art/published issues infringing the priority of the Authors, accordingly there are absolutely NO other intent or restrictions to make the wording text new or original according to your criteria based on the use iThenticate software . The therapeutic modalities described in details in the text and the content of the current submission have been specifically patented by the Author (Dr. Mark A. Babizhayev) with the list of the International PCT patent applications worldwide available and US Patents allowed and pending : WO 94/19325;

14

WO 95/12581; WO 2004/064866 A1 Babizhayev, M.A. and Meguro, K., 2004. COMBINED USE OF CARNOSINASE INHIBITOR WITH L-CARNOSINES AND COMPOSITION. WO 2004/064866 PCT/JP2004/000351. Filed 20 January 2003 (20.01.2003). The Patent Applications and allowed Patents are listed in the scope of the submitted manuscript of the article. Thus, according to the PCT convention and the acting International rules, this work can NOT be considered as plagiarism or self-plagiarism of any kind because all States allocated charges and fees have been timely and accurately payed by Dr. Babizhayev and the priority validity of the Inventions and the contents of the material to the name of Dr. Mark A. Babizhayev and disclosed in this submission has been proved in front of the US Patent Office , European Patent Office and the Japanese Patent Office thus appearing quite original through the World. The present submission of the considered article summarizes the contents of the patented Inventions, Claims and its Specifications which might be remained unchanged in their contents with the major parts . Please, appreciate that according the existing rules of the PCT Convention of Intellectual Property, after filing the PCT applications supporting the priority of the Applicant, the Authors can use any kind of the published material to promote scientifically and industrially this kind of patented Intellectual property, making the due citations where necessary. Obviously, the references to all necessary materials have been duly made punctially in the scope of the considered article. The percentage of repetitions is significantly low, according to your Report. Accordingly , we suggest in compliance with the acting International law, that based on the available International patent protection, we can insist that your reputable Journal can process our submitted work for the review/publication without making revisions as presented by Reviewer for linguistic repetitions in some places of the article as it is obvious that there is no sign of plagiarism in the presented work describing the patented therapeutic modality. As there are factually NO TRACES OF ANY TYPE OF PLAGIARISM in the submitted Manuscript, there are no other reasons to insist on the completely

15

different wording in the text of the article , in view that all due citations in the submitted article have been accurately made. The linguistic phonema used might be legally preserved in several parts of the article for clarity on the distinguished desire of the Authors. Truly, the manuscript overall represents quite original material in its proprietary and other senses with no component of plagiarism existing. It is anticipated that you might be willing to legally traverse the reasons of decline/rejection of our manuscript, if any. The similarities can not be judged as an objective or subjective reason of rejection per se. The linguistic similarities per se are occurred everywhere, Any sentence includes the words that are repeated from time to time, the words in English language contain the similar set of the chosen letters in Latin that are repeated regularly in many sentences through the text as a matter of fact. The linguistic similarities per se can not be the reason of rejections. Now , it is clear to you that there are no traces of plagiarism in our submission, and as such, we have the authorized right to use any information we want to prove our ideas with clarity, supported by the PCT Convention of Intellectual property, we have presented the numbers of the available Patents and International Patent Applications in our possession in the current submission. Your Journal belongs to the International reputable Publishing Scientific House , which Organization should respect the International Laws of Intellectual Properties. Thank you. Kindly, note that there is no personal prejudice or the unrespected attitude to your Journal or Publishers in the above stated disclosure. Thank you very much for your pending amicable and Intellectual consideration of the Problem. Looking forward to hearing from you with the weighted response and pending acceptance of our official position. Thank you. Cordially, Dr. Mark A. Babizhayev, Ph.D., Executive Director, Innovative

16

Vision Products, Inc., DE, USA. Innovative Vision Products, Inc. Delaware Office : 3511 Silverside Road, Suite 105, County of New Castle, Delaware, USA 19810 e-mail: markbabizhayev@yahoo.com Moscow Office : Ivanovskaya 20, Suite 74, Moscow 127434, Russian Federation e-mail: markbabizhayev@mail.ru Tel/Fax: +7(499)977-2387 mobile phone : +7(965)371-79-89 Skype address: Dr_Mark_Babizhayev http://www.innovative-vision-products.com